Search research articles
Contact Us
Filters
Showing results (71-80 of 113) with videos related to
Page
of 12
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
December 3, 2021
Follicular Lymphoma Treated with First-Line Immunochemotherapy: A Review of PET/CT in Patients Who Did Not Achieve a Complete Metabolic Response in the GALLIUM Study
Sally F Barrington, Farheen Mir, Tarec Christoffer El-Galaly, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
April 6, 2005
Pharmacokinetics and biodistribution of 111In- and 177Lu-labeled J591 antibody specific for prostate-specific membrane antigen: prediction of 90Y-J591 radiation dosimetry based on 111In or 177Lu?
Shankar Vallabhajosula, Ichei Kuji, Klaus A Hamacher, et al.
The Journal of Urology
|
October 9, 2003
Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen
Neil H Bander, Edouard J Trabulsi, Lale Kostakoglu, et al.
Radiographics : a Review Publication of the Radiological Society of North America, Inc
|
September 14, 2010
FDG PET with contrast-enhanced CT: a critical imaging tool for laryngeal carcinoma
Mae Mae A Y Chu, Arpakorn Kositwattanarerk, David J Lee, et al.
Cancer
|
August 8, 2013
A phase 2 trial of extended induction epratuzumab and rituximab for previously untreated follicular lymphoma: CALGB 50701
Barbara W Grant, Sin-Ho Jung, Jeffrey L Johnson, et al.
Leukemia & Lymphoma
|
February 28, 2007
Dose-attenuated radioimmunotherapy with tositumomab and iodine 131 tositumomab in patients with recurrent non-Hodgkin's lymphoma (NHL) and extensive bone marrow involvement
Jodi V Mones, Morton Coleman, Lale Kostakoglu, et al.
Leukemia & Lymphoma
|
June 25, 2016
FDG-PET is prognostic and predictive for progression-free survival in relapsed follicular lymphoma: exploratory analysis of the GAUSS study
Lale Kostakoglu, Andre Goy, Giovanni Martinelli, et al.
Molecular Neurodegeneration
|
February 4, 2014
A consecutive case series experience with [18 F] florbetapir PET imaging in an urban dementia center: impact on quality of life, decision making, and disposition
Effie M Mitsis, Heidi A Bender, Lale Kostakoglu, et al.
Leukemia & Lymphoma
|
March 17, 2012
Interim [(18)F]fluorodeoxyglucose positron emission tomography imaging in stage I-II non-bulky Hodgkin lymphoma: would using combined positron emission tomography and computed tomography criteria better predict response than each test alone?
Lale Kostakoglu, Heiko Schöder, Jeffrey L Johnson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 21, 2022
Positron Emission Tomography-Adapted Therapy in Bulky Stage I/II Classic Hodgkin Lymphoma: CALGB 50801 (Alliance)
Ann S LaCasce, Travis Dockter, Amy S Ruppert, et al.
Page
of 12
Search research articles
Search
Showing results (71-80 of 113) with videos related to
Sort By:
Page
of 12
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
December 3, 2021
Follicular Lymphoma Treated with First-Line Immunochemotherapy: A Review of PET/CT in Patients Who Did Not Achieve a Complete Metabolic Response in the GALLIUM Study
Sally F Barrington, Farheen Mir, Tarec Christoffer El-Galaly, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
April 6, 2005
Pharmacokinetics and biodistribution of 111In- and 177Lu-labeled J591 antibody specific for prostate-specific membrane antigen: prediction of 90Y-J591 radiation dosimetry based on 111In or 177Lu?
Shankar Vallabhajosula, Ichei Kuji, Klaus A Hamacher, et al.
The Journal of Urology
|
October 9, 2003
Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen
Neil H Bander, Edouard J Trabulsi, Lale Kostakoglu, et al.
Radiographics : a Review Publication of the Radiological Society of North America, Inc
|
September 14, 2010
FDG PET with contrast-enhanced CT: a critical imaging tool for laryngeal carcinoma
Mae Mae A Y Chu, Arpakorn Kositwattanarerk, David J Lee, et al.
Cancer
|
August 8, 2013
A phase 2 trial of extended induction epratuzumab and rituximab for previously untreated follicular lymphoma: CALGB 50701
Barbara W Grant, Sin-Ho Jung, Jeffrey L Johnson, et al.
Leukemia & Lymphoma
|
February 28, 2007
Dose-attenuated radioimmunotherapy with tositumomab and iodine 131 tositumomab in patients with recurrent non-Hodgkin's lymphoma (NHL) and extensive bone marrow involvement
Jodi V Mones, Morton Coleman, Lale Kostakoglu, et al.
Leukemia & Lymphoma
|
June 25, 2016
FDG-PET is prognostic and predictive for progression-free survival in relapsed follicular lymphoma: exploratory analysis of the GAUSS study
Lale Kostakoglu, Andre Goy, Giovanni Martinelli, et al.
Molecular Neurodegeneration
|
February 4, 2014
A consecutive case series experience with [18 F] florbetapir PET imaging in an urban dementia center: impact on quality of life, decision making, and disposition
Effie M Mitsis, Heidi A Bender, Lale Kostakoglu, et al.
Leukemia & Lymphoma
|
March 17, 2012
Interim [(18)F]fluorodeoxyglucose positron emission tomography imaging in stage I-II non-bulky Hodgkin lymphoma: would using combined positron emission tomography and computed tomography criteria better predict response than each test alone?
Lale Kostakoglu, Heiko Schöder, Jeffrey L Johnson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 21, 2022
Positron Emission Tomography-Adapted Therapy in Bulky Stage I/II Classic Hodgkin Lymphoma: CALGB 50801 (Alliance)
Ann S LaCasce, Travis Dockter, Amy S Ruppert, et al.
Page
of 12